Close
Biotechgate
| |

Home Page

Action required: Please refresh your browser

We have recently implemented some changes that require a hard refresh of your browser: Please hold down the CTRL-key and press the F5 key.
After a successful hard refresh, this message should not appear anymore.

More details about this topic are available here »

Radius Health to Announce Fourth Quarter and Full Year 2019 Financial Results, Host Conference Call and Live Webcast on Thursday, February 27, 2020
By: GlobenewsWire - 13 Feb 2020Back to overview list

WALTHAM, Mass., Feb. 13, 2020 (GLOBE NEWSWIRE) -- Radius Health (Nasdaq: RDUS) announced today that it will release its fourth quarter and full year 2019 financial results on Thursday, February 27, 2020. The Company will host a conference call and live audio webcast at 8:00 a.m. ET that day to discuss the results and provide a company update.

Conference Call Information:
Date: Thursday, February 27, 2020
Time: 8:00 a.m. ET
Domestic Dial-In Number: (866) 323-7965
International Dial-In Number: (346) 406-0961
Conference ID: 2998060

The live webcast of the call can be accessed from the Investors’ section of the Company’s website, https://ir.radiuspharm.com/events-and-presentations. A replay of the conference call/webcast will be available on February 27th at 11:00 a.m. ET and will be archived on the Company's website for 90 days. To access the audio replay, dial (855) 859-2056 U.S. or (404) 537-3406 for International, using conference ID number 2998060.

The full text of the announcement and financial results will also be available on the Company’s website.

About Radius
Radius is a science-driven fully integrated biopharmaceutical company that is committed to developing and commercializing innovative endocrine therapeutics. Radius’ lead product, TYMLOS (abaloparatide) injection, was approved by the U.S. Food and Drug Administration for the treatment of postmenopausal women with osteoporosis at high risk for fracture. The Radius clinical pipeline includes an investigational abaloparatide-patch for potential use in osteoporosis; the investigational drug elacestrant (RAD1901) for potential use in hormone-receptor positive breast cancer; and the investigational drug RAD140, a non-steroidal, selective androgen receptor modulator (SARM) under investigation for potential use in hormone-receptor positive breast cancer. For more information, please visit www.radiuspharm.com.

Investor & Media Relations Contact:
Elhan Webb, CFA
Email: ewebb@radiuspharm.com
Phone: 617-551-4011

Related companies:Radius
Copyright 2020 GlobenewsWire Back to overview list
to the top ↑